Every 10-Q that ZOMEDICA CORP (ZOMDF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZOMDF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZOMDF filings page.
Zomedica Corp., a veterinary health company, reported Q2 2026 net revenue of 9,512 (thousands of U.S. dollars), up from 6,964 a year earlier. Gross profit increased to 6,041, while operating loss narrowed to 4,083 and net loss to 3,765.
For the first six months of 2026, net revenue rose to 18,311 from 13,464, and net loss improved to 8,299 from 71,207, reflecting the absence of prior-year impairment charges of 55,833 for goodwill and intangible assets and 1,981 for property and equipment. General and administrative, research and development, and selling and marketing expenses all declined year over year.
Therapeutic Devices remained the largest segment with six‑month revenue of 12,575, while Diagnostics contributed 2,351 and Development Services 3,385. At June 30, 2026, cash and cash equivalents were 7,194 and available-for-sale securities 36,940, supporting shareholders’ equity of 107,284 against total liabilities of 10,863.
Zomedica Corp. reported higher revenue but a small net loss for the quarter ended March 31, 2026. Net revenue rose to $8,799 from $6,500 a year earlier, driven mainly by Therapeutic Devices and new Development Services revenue.
Gross profit increased to $5,484 from $4,407, while operating expenses fell sharply because the prior-year period included large impairment charges. The company posted a net loss of $4,534, a major improvement from a $63,809 loss in the prior-year quarter.
Zomedica ended the quarter with $9,369 in cash and cash equivalents and $44,965 of investment securities, against total liabilities of $10,588. All three segments—Diagnostics, Therapeutic Devices, and Development Services—generated revenue, with U.S. customers providing most sales.
Zomedica Corp. reported Q3 results showing modest growth and continued losses. Net revenue rose to $8,095 (from $6,997) with gross profit of $5,436 (from $5,060). The company recorded a Q3 net loss of $6,121 (vs. $6,697). Year‑to‑date, revenue reached $21,559 (from $19,390) while net loss widened to $77,328, largely due to $55,833 of non‑cash impairment recorded earlier in 2025.
Cash and cash equivalents were $7,496 with $45,628 of current available‑for‑sale securities and $1,242 noncurrent. Total assets were $130,905 and shareholders’ equity was $119,688. Goodwill was fully written off in 2025, including $45,556 of impairments in Therapeutic Devices, and $8,300 of intangible impairments primarily in Diagnostics. Zomedica introduced a new Development Services segment in Q3 contributing $662 of revenue. Therapeutic Devices remained the core driver with Q3 revenue of $6,671, while Diagnostics delivered $762. Common shares outstanding were 979,949,668 as of November 3, 2025.